97 related articles for article (PubMed ID: 9623882)
1. Cisplatin resistance in cyclic AMP-dependent protein kinase mutants.
Cvijic ME; Yang WL; Chin KV
Pharmacol Ther; 1998 May; 78(2):115-28. PubMed ID: 9623882
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin.
Cvijic ME; Chin KV
Int J Cancer; 1997 Jul; 72(2):345-50. PubMed ID: 9219844
[TBL] [Abstract][Full Text] [Related]
3. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants.
Liu B; Cvijic ME; Jetzt A; Chin KV
Cell Growth Differ; 1996 Aug; 7(8):1105-12. PubMed ID: 8853907
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin sensitivity in cAMP-dependent protein kinase mutants of Saccharomyces cerevisiae.
Cvijic ME; Yang WL; Chin KV
Anticancer Res; 1998; 18(5A):3187-92. PubMed ID: 9858882
[TBL] [Abstract][Full Text] [Related]
6. Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants.
Cvijic ME; Chin KV
Cell Growth Differ; 1997 Dec; 8(12):1243-7. PubMed ID: 9419412
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of protein kinase A - RIalpha reduces lipofection efficiency of cisplatin-resistant human tumor cells.
Son KK; Rosenblatt J
Cancer Lett; 2001 Apr; 165(1):81-6. PubMed ID: 11248422
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the regulatory subunit of the cAMP-dependent protein kinase with PATZ1 (ZNF278).
Yang WL; Ravatn R; Kudoh K; Alabanza L; Chin KV
Biochem Biophys Res Commun; 2010 Jan; 391(3):1318-23. PubMed ID: 20026299
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
Nesterova MV; Cho-Chung YS
Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
[TBL] [Abstract][Full Text] [Related]
10. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
Nesterova MV; Cho-Chung YS
Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
[TBL] [Abstract][Full Text] [Related]
11. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells.
Parissenti AM; Gannon BR; Villeneuve DJ; Kirwan-rhude AF; Chadderton A; Glück S
Int J Cancer; 1999 Sep; 82(6):893-900. PubMed ID: 10446459
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
Nesterova M; Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
[TBL] [Abstract][Full Text] [Related]
13. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
14. A kinase anchoring protein (AKAP) interaction and dimerization of the RIalpha and RIbeta regulatory subunits of protein kinase a in vivo by the yeast two hybrid system.
Carlson CR; Ruppelt A; Taskén K
J Mol Biol; 2003 Mar; 327(3):609-18. PubMed ID: 12634056
[TBL] [Abstract][Full Text] [Related]
15. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
16. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex.
Robinson-White A; Meoli E; Stergiopoulos S; Horvath A; Boikos S; Bossis I; Stratakis CA
J Clin Endocrinol Metab; 2006 Jun; 91(6):2380-8. PubMed ID: 16569736
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance and oncogenes--a review.
Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
[TBL] [Abstract][Full Text] [Related]
18. Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency.
Mavrakis M; Lippincott-Schwartz J; Stratakis CA; Bossis I
Hum Mol Genet; 2006 Oct; 15(19):2962-71. PubMed ID: 16963469
[TBL] [Abstract][Full Text] [Related]
19. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells.
Naviglio S; Di Gesto D; Illiano F; Chiosi E; Giordano A; Illiano G; Spina A
J Cell Physiol; 2010 Nov; 225(3):801-9. PubMed ID: 20589829
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
